10 August 2015 -  Dasabuvir (trade name Exviera) and the fixed-dose drug combination ombitasvir/paritaprevir/ritonavir (trade name Viekirax) have been available since January 2015 for the treatment of adults with chronic hepatitis C infection. The German Institute for Quality and Efficiency in Health Care (IQWiG) had examined their added benefit in a dossier assessment completed in April 2015.

In an addendum, the Institute now assessed study data subsequently submitted by the drug manufacturer in the commenting procedure. According to the findings, the results of an indirect comparison show a hint of an added benefit of both drugs also in pretreated patients with genotype 1b infection without cirrhosis. The extent of this added benefit is non-quantifiable.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/dasabuvir-and-ombitasvir/paritaprevir/ritonavir-hint-of-added-benefit-in-further-patients.6757.html